- Home
- GSIW vs GTBP Comparison
GSIW vs GTBP Comparison
Compare GSIW & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSIW | GTBP |
|---|---|---|
| Founded | 2016 | 1965 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 13.0M |
| IPO Year | 2022 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GSIW | GTBP |
|---|---|---|
| Price | $14.40 | $9.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 48.3K | ★ 381.1K |
| Earning Date | 08-04-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.22 |
| 52 Week High | $38.55 | $8.82 |
Technical Indicators
Market Signals| Indicator | GSIW | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 35.90 | 99.19 |
| Support Level | $13.46 | $0.38 |
| Resistance Level | $18.03 | N/A |
| Average True Range (ATR) | 1.71 | 0.65 |
| MACD | 0.12 | 1.13 |
| Stochastic Oscillator | 32.12 | 97.02 |
Price Performance
Historical ComparisonAbout GSIW Garden Stage Limited
Garden Stage Ltd, through its subsidiaries is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; asset management services; investment advisory services; due diligence services; and introduction and referral services. The company operates in a single segment and derives all of its revenue from Hong Kong.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.